Instinet

Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cell therapies, specifically autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of cancer. The company's proprietary Co-Stimulatory Antigen Receptor (CoStAR) platform is designed to enhance the efficacy of TILs by providing a co-stimulatory signal upon binding to tumor-associated antigens, potentially overcoming the immunosuppressive tumor microenvironment. While the company recently discontinued its licensed bispecific antibody programs (AXN-2510 and AXN-27M) in early 2026, it continues to advance its lead engineered TIL candidate, ITIL-306. Instil Bio aims to address a broad range of solid tumors, including ovarian and lung cancers, through its innovative cell engineering approach.